272 results about "Cardiomyopathy" patented technology

The invention relates to the technical field of pharmaceutical preparations, in particular to a rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition and a preparation method thereof, and the rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition comprises a quick release layer, a slow release layer and an osmotic pump structural design. According to the application, staged or constant-rate release of rapamycin within 168 hours is realized through a multi-phase release technology or an osmotic pump technology, and the problems that an existing preparation is large in blood concentration fluctuation, high in administration frequency and low in bioavailability are solved. The composition is suitable for treating hypertrophic cardiomyopathy of cats, significantly improves cardiac functions and reduces side effects and risks, is administered once a week, and is convenient to use. The invention further provides a storage method, and the product stability is ensured. The technical scheme has remarkable clinical advantages and application prospects.

The invention discloses a hypertrophic cardiomyopathy (HCM) preoperative planning and operation effect evaluation method based on accurate digital labeling. The method comprises the following steps: performing digital labeling on the thickness of each wall of a left ventricle of a preoperative heart 3D digital model; according to the digital labeling result of the preoperative heart 3D digital model and the normal value of the thickness of the left ventricular wall, a doctor manually depicts the predicted resection range and confirms the predicted retention thickness; measuring the predicted resection volume, the predicted resection area and the left ventricular end diastolic volume after the predicted resection volume is resected; digitally marking the thickness of each wall of the left ventricle of the postoperative heart 3D digital model, and measuring the volume of the corresponding left ventricle in the end diastole; and taking the predicted resection range, the predicted retention thickness, the predicted resection volume, the predicted resection area and the predicted volume as first evaluation data, taking corresponding parameters of the postoperative heart 3D digital model as second evaluation data, and generating an operation evaluation result according to the conformity of the first evaluation data and the second evaluation data.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The invention relates to the technical field of medicine preparation, in particular to application of a microRNA244-5P inhibitor in preparation of a product for treating sepsis cardiomyopathy. According to the application of the microRNA 244-5P inhibitor in the preparation of the product for treating the sepsis cardiomyopathy, the sequence of the microRNA 244-5P inhibitor is shown as Seq. ID No. 1, and the microRNA 244-5P inhibitor can be applied to the preparation of the product for treating the sepsis cardiomyopathy. The provided microRNA 244-5P inhibitor lays a precise foundation for targeted treatment of sepsis cardiomyopathy. The inhibitor can specifically recognize and act on related targets, accurately intervene the pathological process of sepsis cardiomyopathy, has more stable structure and activity, can ensure that the inhibition effect can be continuously and efficiently played when a treatment product is prepared, provides a clear material basis and a technical basis for research, development, production and quality control of subsequent products, and has a wide application prospect. The pertinence and the effectiveness of treatment are greatly improved.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The present disclosure provides a method of treating cardiomyopathy and / or related heart failure in a human subject (e.g., an adult human subject) in need of such treatment with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of treating portal hypertension in a human subject (e.g., an adult human subject) in need of such treatment with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of treating clinically significant portal hypertension (CSPH) in a human subject (e.g., an adult human subject) in need of such treatment with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.

This invention discloses the application of alismazone B acetate in the preparation of drugs for the prevention or treatment of hypertrophic cardiomyopathy and its related symptoms. This invention is the first to propose the use of alismazone B acetate (AB23a) for the prevention or treatment of hypertrophic cardiomyopathy. The invention utilizes AB23a to directly treat cardiomyocytes obtained from directed differentiation of human embryonic stem cells in vitro, finding that AB23a treatment significantly inhibits the hypertrophic phenotype of human embryonic stem cell-cardiomyocytes. Feeding mice with hereditary hypertrophic cardiomyopathy caused by gene mutations to a diet containing AB23a showed that AB23a significantly alleviated pathological myocardial hypertrophy and improved cardiac function in mice. AB23a can be used to prepare drugs against hereditary hypertrophic cardiomyopathy, providing a new approach and method for treating hypertrophic cardiomyopathy. AB23a is the most important medicinal component of the traditional Chinese medicine Alisma plantago-aquatica, is safe for organisms, and has good clinical application prospects.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention provides a radiofrequency ablation instrument for treating heart diseases, and relates to the technical field of medical equipment. The radiofrequency ablatometer comprises a man-machine interaction device, a data processing device, a radiofrequency energy generating device, an ablation device, an ablation parameter acquisition device, a twelve-lead ECG signal acquisition device, an ultrasonic image acquisition device, a vital sign monitoring acquisition device and a circulating cooling device which are respectively connected with the radiofrequency energy generating device and the ablation device, the cooling device is used for supplying cooling liquid to the ablation device; the data processing device controls power output of the radio frequency energy generating device according to the twelve-lead ECG signals and ablation parameters, and the man-machine interaction device displays ultrasonic images, vital sign parameters and ECG data. According to the invention, concentrated display and linkage analysis of ultrasonic images, twelve-lead ECG signals and vital sign parameters are realized for the first time, and the device can be widely applied to percutaneous intracardiac radiofrequency ablation treatment of hypertrophic cardiomyopathy, cardiac tumor and other diseases, and has extremely high clinical application value.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

One aim of the present invention is to treat or prevent hypertrophic cardiomyopathy. Provided are: a pharmaceutical composition for treatment or prevention of hypertrophic cardiomyopathy comprising a compound inhibiting SGLT1 or a pharmaceutically acceptable salt thereof; and a method of treating or preventing hypertrophic cardiomyopathy, comprising administering a compound inhibiting SGLT1 or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a KAT6A inhibitor in preparation of a medicine for treating diabetic cardiomyopathy. Specifically, the invention relates to an application of a histone acetyltransferase inhibitor in preparation of drugs for treating or preventing diabetic cardiomyopathy. The invention discloses an application of a KAT6A inhibitor in preparation of a medicine for treating diabetic cardiomyopathy, which is used for treating or preventing diabetic cardiomyopathy by inhibiting acetylation modification of dihydrolipoamide transacetylase protein and inhibiting cell copper death.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

The present invention relates to Givinostat hydrochloride monohydrate for use in the treatment of arrhythmogenic cardiomyopathy.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The invention provides an LMNA mutant gene and application thereof, and belongs to the technical field of biomedicine. The nucleotide sequence of the human LMNA mutant gene is as shown in SEQ ID NO. 1. The LMNA mutant gene can be used for screening dilated cardiomyopathy and atrioventricular block and constructing a non-human animal model of the dilated cardiomyopathy and the atrioventricular block, and is beneficial to exploring pathophysiological processes of the dilated cardiomyopathy and the atrioventricular block and exploring therapeutic targets and drugs of the dilated cardiomyopathy and the atrioventricular block.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The application provides a traditional Chinese medicine and diet dispensing device for diabetic cardiomyopathy patients, and relates to the technical field of diet dispensing equipment. The device comprises a box body, a storage area, a discharge area and a receiving area are arranged in the box body from top to bottom; the storage area is composed of multiple storage cavities, the discharge area is provided with a spiral conveying and discharging mechanism, the receiving area is provided with a weighing receiving structure, and a self-cleaning mechanism and a control system are further arranged. The device can realize quantitative storage, automatic discharge, accurate weighing and integrated dispensing of various medicinal and edible materials, and meets the needs of traditional Chinese medicine and diet formula of diabetic cardiomyopathy patients; the self-cleaning mechanism can complete internal flushing, avoid food residue pollution and ensure health safety. The overall structure is compact, the control is accurate and the operation is convenient, which can effectively improve the standardization and automation level of traditional Chinese medicine and diet dispensing, and solve the problems of low efficiency, inaccurate measurement and cross contamination in manual dispensing.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

This disclosure relates to the field of nucleic acid drug technologies, and in particular to a small RNA-based drug, preparation, and use thereof in prophylaxis and / or treatment of cardiomyopathy. Provided is a novel small RNA with the nucleotide sequence of SEQ ID NO: 10. The small RNA exhibits good structural stability, marked efficacy at 24 h, and high affinity to nascent polypeptide-associated complex α (NACα) protein. With strong activity to suppress the expression of pyroptosis-related proteins, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and gasdermin D (GSDMD), the small RNA can effectively protect cardiomyocytes and enhance the therapeutic effect on diabetic cardiomyopathy (DCM). Furthermore, the small RNA posses advantages of low effective concentration and high biosafety, highlighting its potential for clinical drug development and application as a nucleic acid drug.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The application discloses that 5-oxoproline can be used as a biomarker for diagnosing chemotherapy-induced cardiomyopathy, and for the first time provides a blood metabolic marker for assisting in predicting and early diagnosing chemotherapy drug-induced cardiomyopathy, which has high accuracy and diagnostic reference value. By accurately determining the content of the small molecule metabolic marker 5-oxoproline in blood, the diagnosis of early myocardial injury induced by chemotherapy drugs will no longer completely rely on conventional non-specific myocardial injury markers and imaging methods, but will rely on the content change of metabolic products in the blood of patients as an objective index, thus advancing the time window for discovering subclinical myocardial injury, significantly improving the early diagnosis detection rate, simplifying the diagnosis process, providing an opportunity for early intervention, helping to prevent or reverse the further aggravation of chemotherapy-induced cardiomyopathy, and thus improving the overall survival prognosis of tumor patients.

The present invention belongs to the technical field of pulsed electric field ablation for hypertrophic cardiomyopathy, and specifically relates to a pulsed electric field ablation device for hypertrophic cardiomyopathy. The device comprises a pulse generator (1). A flexible catheter (2) is fixedly mounted on one side of the pulse generator (1), and a slidably connected sliding member (3) is arranged on the outer surface of the flexible catheter (2). By means of the arrangement of an auxiliary ablation assembly (6), a real-time three-dimensional echocardiography can be generated during the ablation process, and a relatively clear cardiac structure image can be provided for a doctor by means of the three-dimensional echocardiography, such that the doctor can better determine the region of hypertrophied myocardium. Moreover, data analysis is performed on the hearts of a large number of patients by means of artificial intelligence and a machine learning algorithm inside a high-speed analog-to-digital converter to generate a personalized cardiac model, so as to assist the doctor in accurate positioning, thereby reducing the number of times of adjusting the position of a PFAD electrode catheter, shortening the time required by the doctor during surgery, and reducing the difficulty of surgery treatment.

The invention provides a 4-amino-2, 6-dihydroxypyrimidine derivative and application thereof.The 4-amino-2, 6-dihydroxypyrimidine derivative has the structure shown in the formula I. The 4-amino-2, 6-dihydroxypyrimidine derivative can be used as a small-molecule inhibitor for inhibiting the function of myosin ATPase, and the application of the 4-amino-2, 6-dihydroxypyrimidine derivative can be used for preparing a myosin ATPase inhibitor. The method can be used as an effective means for treating and preventing hypertrophic cardiomyopathy.

The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the TTR gene. Methods of using such RNAi constructs to treat or prevent cardiac disease, such as transthyretin-associated cardiomyopathy (ATTR-CM), are also described.